Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer.
Daniel Alonso-MiguelGuillermo ValdiviaDiego GuerreraMaría Dolores Pérez AlenzaStanislav PantelyushinAngela Alonso-DiezVeronique BeissSteven N FieringNicole F SteinmetzMaria Suarez-RedondoJohannes Vom BergLaura PeñaHugo Arias-PulidoPublished in: Journal for immunotherapy of cancer (2022)
Neoadjuvant in situ eCPMV immunotherapy demonstrated anti-tumor efficacy and improved survival in IMC patients without systemic adverse effects. eCPMV-induced changes in immune cells point to neutrophils as a driver of immune response. Neoadjuvant in situ eCPMV immunotherapy could be a groundbreaking immunotherapy for canine IMC and a potential future immunotherapy for human IBC patients.
Keyphrases
- end stage renal disease
- immune response
- rectal cancer
- ejection fraction
- newly diagnosed
- chronic kidney disease
- lymph node
- peritoneal dialysis
- prognostic factors
- locally advanced
- endothelial cells
- oxidative stress
- mesenchymal stem cells
- risk assessment
- stem cells
- squamous cell carcinoma
- free survival
- replacement therapy